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The signaling mechanisms underlying the effects of
angiotensin II in proximal tubules of the kidney are not
completely understood. Here we measured signal protein
phosphorylation in isolated proximal tubules using pathway-
specific proteomic analysis in rats continuously infused with
pressor or non-pressor doses of angiotensin II over a 2-week
period. Of the 38 phosphoproteins profiled, 14 were
significantly altered by the pressor dose. This included
increased phosphorylation of the protein kinase C
isoenzymes, PKCa and PKCbII, and the glycogen synthase
kinases, GSK3a and GSK3b. Phosphorylation of the
cAMP-response element binding protein 1 and PKCd were
decreased, whereas PKCe remained unchanged. By contrast,
the phosphorylation of only seven proteins was altered by
the non-pressor dose, which increased that of PKCa, PKCd,
and GSKa. Phosphorylation of MAP kinases, ERK1/2, was not
increased in proximal tubules in vivo by the pressor dose,
but was in proximal tubule cells in vitro. Infusion of the
pressor dose decreased, whereas the non-pressor dose of
angiotensin II increased the phosphorylation of the sodium
and hydrogen exchanger 3 (NHE-3) in membrane fractions
of proximal tubules. Losartan largely blocked the signaling
responses induced by the pressor dose. Thus, PKCa and
PKCbII, GSK3a and GSK3b, and cAMP-dependent signaling
pathways may have important roles in regulating proximal
tubular sodium and fluid transport in Ang II-induced
hypertensive rats.
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Angiotensin II (Ang II) has a critical role in the regulation
of sodium and fluid reabsorption in proximal tubules of
the kidney in both physiological and diseased states. The
evidence supporting the important roles of Ang II in
proximal nephrons is quite overwhelming.1–3 In isolated
proximal tubule preparations or cultured proximal tubule
cells, Ang II stimulates the expression or activities of the
sodium and hydrogen exchanger-3 (NHE-3),4,5 the sodium
and potassium ATPase (Naþ /Kþ -ATPase),6,7 or the sodium
and bicarbonate co-transporter (Naþ /HCO3
).8,9 In acute
in vivo micropuncture or in vitro microperfusion studies,
peritubular and intraluminal Ang II infusion induces biphasic
transport responses, with picomolar doses of Ang II stimulate
sodium transport while nanomolar doses inhibit sodium
transport.1,10 Sustained increases of circulating and tissue Ang
II levels in proximal tubules in experimental animals,
however, are associated with high blood pressure, sodium
retention, and tubulointerstitial injury in the kidney.11–13
Signaling mechanisms mediating the physiological or
pathophysiological effects of Ang II in proximal tubules of
the kidney remain incompletely understood. Our current
understanding of Ang II-dependent signaling mechanisms is
based primarily on studies in cultured proximal tubule cells
or in isolated proximal tubules. In vitro, Ang II activates
several heterotrimeric G-proteins including Gq/11, Gs, Gi, G12,
and G13.
14–16 The activated downstream signaling proteins
range from inositol triphosphate, calcium, diacylglycerol,
adenylyl cyclase/cAMP, and protein kinase C (PKC) to other
receptor and non-receptor tyrosine kinases and serine/
threonine kinases, such as the MAP kinase family (ERK,
JNK, and p38 MAPK).15,17 However, it is not clear whether
similar signaling mechanisms may be replicated in an
integrative physiological or pathophysiological setting.
The present study used a novel pathway-specific proteo-
mic approach to study the responses of 38 major signaling
phosphoproteins in proximal tubules of the rats treated
with 2-week infusion of a pressor or a non-pressor dose of
Ang II. Ang II-infused rats were treated with the AT1 receptor
blocker losartan to determine the role of AT1 receptors.
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In order to exclude the contamination of signaling proteins
from adjacent glomeruli, blood vessels, or cortical collecting
ducts, we isolated fresh proximal tubules specifically from
the superficial cortex of the kidney for proteomic analysis of
signaling responses to Ang II.
RESULTS
Effects of the pressor dose of Ang II infusion on blood
pressure and renal excretory function
Infusion of Ang II (60 ng/min, s.c.) for 2 weeks markedly
increased systolic blood pressure in Ang II-infused rats
(Table 1; Po0.01). Compared with control, Ang II mode-
rately increased urinary water and sodium excretion and
decreased urine osmolality. Urinary albumin-to-creatinine
ratio was increased by threefold in Ang II-infused rats. These
responses to the pressor dose of Ang II infusion were
normalized by losartan treatment.
Effects of the pressor dose of Ang II infusion on circulating
and intrarenal Ang II
Infusion of the pressor dose of Ang II for 2 weeks signif-
icantly increased plasma and whole kidney Ang II levels in
rats (Figure 1). Plasma Ang II was increased by 2.8-fold in
Ang II-infused rats (control: 115.5±24.1 fmol/ml versus
Ang II-infused: 323±34.4 fmol/ml; Po0.01). Concurrent
losartan treatment in Ang II-infused rats further elevated
plasma Ang II levels above those of control and Ang II-infused
rats because of AT1 receptor occupancy by losartan
(421.6±32.3 fmol/ml; Po0.01). Kidney Ang II was increased
by twofold (control: 172.6±16.2 pg/g versus Ang II-infused:
336.5±25.7 pg/g kidney weight; Po0.01), which was blocked
by losartan in Ang II-infused rats (205.1±19.3 pg/g kidney
weight, Figure 1). Proximal tubular Ang II was also increased by
2.6-fold (control: 61.7±8.9 versus Ang II-infused: 162.3±
34.9 pg/mg proteins; Po0.01), which was decreased by losartan
in Ang II-infused rats (55.7±9.7 pg/mg proteins, Po0.01).
Effects of the pressor dose of Ang II infusion and losartan
treatment on pathway-specific signaling phosphoproteins
Figure 2 shows multi-immunoblots of 38 signaling phos-
phoproteins in proximal tubules of control (Figure 2a), the
pressor dose of Ang II-infused (Figure 2b), and losartan-
treated Ang II-infused rats (Figure 2d). Figure 2c shows the
colored overlay of multi-immunoblots of 38 phosphoproteins
in proximal tubules of control (Figure 2a) and Ang II-infused
rats (Figure 2b). Figure 2e is the colored overlay of
control (Figure 2a) and losartan-treated, Ang II-infused rats
Table 1 | Effects of the pressor dose of Ang II infusion and concurrent losartan treatment for 2 weeks on body and kidney
weights, systolic blood pressure, 24 h urinary excretion of water, and electrolytes in Ang II-infused rats
Response Control Ang II Ang II+losartan
Body weight, g 322±8 316±7 300±5
Kidney weight, g 2.5±0.3 2.4±0.3 2.4±0.2
Kidney weight/body weight ratio, 100 0.76±0.02 0.79±0.03 0.79±0.02
SBP, mmHg 118±5 175±7** 126±8ww
Urine, ml/24 h 12.7±0.5 20.1±0.6** 13.5±0.72ww
UNaV, mmol/24 h 1.67±0.05 2.17±0.09* 1.64±0.09
ww
UKV, mmol/24 h 2.32±0.16 2.61±0.22 2.78±0.31
Urine osmolality, mOsm/kg H2O 1535±28 943±26* 1162±32*
w
Urine albumin/creatinine ratio, mg/g 21.6±2.8 79.1±11.9** 26.8±5.8ww
Abbreviations: Ang, angiotensin; SBP, systolic blood pressure; UKV, urinary potassium excretion; UNaV, urinary sodium excretion. *Po0.05 or **Po0.01 versus control. wPo0.05
or wwPo0.01 versus Ang II-infused hypertensive rats.
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Figure 1 | Effects of 2-week infusion of the pressor dose of
angiotensin (Ang) II and concurrent losartan (los) treatment
on plasma (top), whole kidney (middle), and proximal
tubule Ang II levels in rats (bottom). Proximal tubule Ang II is
expressed as pg per mg protein, not as wet weight. **Po0.01,
compared with controls; wwPo0.01, compared with angiotensin
(Ang) II-infused hypertensive rats.
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(Figure 2d), whereas Figure 2f is the colored overlay of Ang
II-infused (Figure 2b) and losartan-treated, Ang II-infused
rats (Figure 2d). The Kinetwork multi-immunoblot proteo-
mic analyses identified (Kinexus Bioinformatics, Vancouver,
Canada) 14 signaling phosphoproteins that were altered by
425% in proximal tubules of the Ang II-infused rats for 2
weeks (Figure 3). Phosphoproteins that were not altered by
Ang II are listed in Table 2. Losartan largely, but not
completely, blocked the signaling responses to Ang II and
restored the phosphoproteins to untreated levels.
cAMP-dependent CREB1 signaling phosphoproteins. Phos-
pho-CREB1 immunofluorescence staining was much weaker
in proximal tubules of Ang II-infused rats than in control
rats, and the response was reversed by losartan (Figure 4a-c).
Ang II decreased phosphorylated CREB1 [S133] proteins in
proximal tubules by 56±7% (Po0.01). Concurrent treat-
ment with losartan restored phospho-CREB1 proteins to the
control level in Ang II-infused rats (Po0.01).
Protein kinase C signaling phosphoproteins. Angiotensin II
markedly increased phospho-PKCa [S657] immunofluorescence
staining in proximal tubules of Ang II-infused rats, which
was reversed by losartan (Figure 5a–c). Western blot analysis
confirmed that phospho-PKCa [S657] was increased by
86±9% in membrane fractions, but was decreased in
cytosolic fractions (Po0.01, Figure 5d). Activation of PKCa
[S657] in proximal tubules by Ang II was blocked by losartan.
Phospho-PKCa/bII [T638/T641] was increased by 122±13%
in Ang II-infused rats (Po0.01), which was also blocked by
losartan (see Supplementary Figure S1 online). By contrast,
PKCd [T507] phosphoproteins were decreased by 53±9% in
proximal tubules by Ang II (Po0.01), and the response was
blocked by losartan (Po0.01 versus Ang II-infused) (see
Supplementary Figure S1 online). PKCe [S729] phosphopro-
teins were not altered in Ang II-infused rats with or without
losartan treatment.
Glycogen synthase kinase 3 signaling phosphoproteins. Figure 6
shows that glycogen synthase kinase 3 (GSK3) (aþ b)/
[Y216þY279] phosphoproteins were increased by 56±9%
(Po0.01) and 140±11% (Po0.01), respectively, in proximal
tubules of Ang II-infused rats. Again, losartan completely
blocked these responses.
MAP kinase signaling phosphoproteins. MAP kinases
ERK1/ERK2 [T202þY204] phosphoproteins were decreased
by 44±5% in proximal tubules of Ang II-infused rat kidneys
(Po0.05 versus control). Losartan treatment blocked these
responses (see Supplementary Figure S2 online).
a d
b
c f
e
Figure 2 | Effects of 2-week infusion of the pressor dose of Ang II and concurrent losartan treatment on the activation or inhibition
of 38 signaling phosphoproteins in proximal tubules of the rat kidneys. (a) Control; (b) angiotensin (Ang) II-infused; and
(c) colored overlay of pooled control (a) and Ang II-infused (b) rat proximal tubule samples. Panel (d) losartan-treated Ang II-infused
rats. (e) Colored overlay of pooled control (a) and losartan-treated Ang II-infused rat proximal tubule samples (d). (f) Colored overlay
of pooled Ang II-infused (b) and losartan-treated Ang II-infused (d) rat proximal tubule samples. Abbreviations for the tracked signaling
phosphoproteins are explained in Table 4. Red shows increased whereas blue indicates decreased signaling phosphoproteins in response to
the pressor dose of Ang II infusion, compared with control or losartan-treated, Ang II-infused rats. White shows unaltered signaling
phosphoproteins in response to Ang II infusion.
622 Kidney International (2011) 80, 620–632
or ig ina l a r t i c l e XC Li and JL Zhuo: AT1 receptor signaling phosphoproteins in proximal tubules
Effects of the pressor dose of Ang II infusion on [125I]Val5-Ang
II binding and AT1 receptor expression
Specific [125I]Val5-Ang II receptor binding was localized in
the glomeruli and proximal tubules of the cortex and in the
inner stripe of the outer medulla (Figure 7). Ang II infusion
decreased [125I]Val5-Ang II binding by 50% in the cortex
(control: 183±8 dpm/mm2 versus Ang II: 90±12 dpm/mm2;
Po0.01) and in the inner stripe of the outer medulla (control:
276±13 dpm/mm2 versus Ang II: 128±6 dpm/mm2; Po0.01).
Losartan largely blocked 490% of [125I]Val5-Ang II binding
in the kidney (15±3 dpm/mm2, Po0.01). AT1 protein was
measured by western blot analysis in membrane fractions
of isolated proximal tubules, which was decreased in Ang II-
infused rats (control: 0.24±0.02 versus Ang II: 0.09±0.02 AT1/
actin ratio, Po0.01) and restored by losartan (Figure 7e).
Effects of the pressor dose of Ang II infusion on
phosphorylated NHE-3 proteins
In untreated rats, phospho-NHE-3 immunofluorescence
staining was distributed throughout the wall of proximal
tubules (Figure 8a), which was much weaker in Ang II-
infused rats (Figure 8b). Concurrent losartan treatment
largely restored phospho-NHE-3 immunofluorescence stain-
ing to the control level (Figure 8c). In membrane fractions of
freshly isolated proximal tubules, phospho-NHE-3 proteins
were decreased in Ang II-infused rats (control: 0.24±0.02
versus Ang II: 0.10±0.03 NHE-3/actin ratio, Po0.01).
Losartan again restored membrane phospho-NHE-3 proteins
to the control level (Figure 8d). Interestingly, NHE-3 mRNA
expression was increased in proximal tubules of the rats
treated with the pressor dose of Ang II infusion, probably
because of the feedback response to the decreased membrane
(or total) phospho-NHE-3 proteins in proximal tubules
(see Supplementary Figure S3 online). Again, losartan
reversed the NHE-3 mRNA response to the pressor dose of
Ang II infusion (see Supplementary Figure S3 online).
Effects of the non-pressor dose Ang II infusion on blood
pressure, urinary electrolyte excretion, AT1 and NHE-3
activation, and signaling phosphoproteins
Table 3 summarizes blood pressure and renal electrolyte
responses to infusion of the non-pressor dose of Ang II
(15 ng/min, s.c.) and concurrent losartan treatment for
2 weeks. Systolic blood pressure was not changed by Ang II,
but it was decreased by losartan. Twenty-four hour urine
excretion was also unaltered, accompanied by a small decrease
in 24-h urinary sodium excretion. AT1 receptor proteins were
increased by Ang II (control: 0.26±0.03 versus Ang II:
0.42±0.03 AT1/actin ratio, Po0.01), which was blocked by
losartan (see Supplementary Figure S4 online). Compared with
control (Figure 9a), phospho-NHE-3 immunofluorescence
staining was stronger in proximal tubules of Ang II-infused
rats (Figure 9b), which was reversed by losartan (Figure 9c).
Furthermore, phospho-NHE-3 proteins were increased in
membrane fractions of proximal tubules by the non-pressor
dose of Ang II (control: 0.18±0.03 versus Ang II: 0.38±0.06
NHE-3/actin ratio, Po0.01) (Figure 9d). Interestingly,
PKCa [S657] and PKCd [T507], but not PKCbII or PKCe,
and GSK3a [Y279], but not GSK3b [Y216], were activated
by the non-pressor dose of Ang II (Figure 10a–d).
Effects of Ang II on MAP kinases ERK1/2 signaling
phosphoproteins in cultured mouse proximal tubule cells
The lack of effects of the pressor dose of Ang II infusion on
ERK1/2 signaling phosphoproteins in proximal tubules by
Kinetwork multi-immunoblot analysis prompted us to test
whether Ang II activates ERK/1/2 in wild type and AT1a-KO
mouse proximal tubule cells with the knock-in of a wild-type
AT1a receptor (Figure 11). In wild-type cells, Ang II induced
dose- and time-dependent increases in phospho-ERK1/2
with peak responses at 10 nmol/l (Figure 11a), and at 5 to
10min, respectively, (Figure 11b). Ang II (10 nmol/l)
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Figure 3 | The Kinetwork multi-immunoblot and semi-
quantitative analyses identified 14 signaling phospho-
proteins that were altered in proximal tubules by 2-week
infusion of the pressor dose of angiotensin (Ang) II in rats.
The relative changes in the enhanced chemiluminescence (ECL)
western signal intensity are expressed as c.p.m., which is the
trace quantity of the band corrected to a scan time of 60 s
(see online Expanded Methods section).
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increased phospho-ERK1/2 by 2.6-fold (control: 0.28±0.05
versus Ang II: 0.73±0.12 p-ERK1/2 to t-ERK1/2 ratio,
Po0.01), which was blocked by losartan (0.46±0.06
p-ERK1/2 to t-ERK1/2 ratio, Po0.01 versus Ang II)
(Figure 11). No biphasic p-ERK1/2 responses to Ang II were
observed. In AT1a-KO cells, Ang II had little effect on
p-ERK1/2 (not shown), but knock-in of the AT1a receptor in
these cells restored the p-ERK1/2 response to Ang II (control:
0.16±0.05 versus Ang II: 0.62±0.08, p-ERK1/2 to t-ERK1/2
ratio, Po0.01). Losartan blocked the effect of Ang II on
p-ERK1/2 in AT1a-KO cells with the knock-in of the AT1a
receptor (0.36±0.06 p-ERK1/2 to t-ERK1/2 ratio, Po0.01
versus Ang II) (Figure 11).
Effects of knockdown of PKCa protein expression on Ang II-
induced NHE-3 activation in mouse proximal tubule cells
We determined whether activation of PKCa signaling
phosphoproteins is actually involved in the activation or
Table 2 | Signaling phosphoproteins that were not significantly altered by the pressor dose of Ang II-infusion or concurrent
treatment with losartan in Ang II-infused rats (o25% increase or decrease)
Proteins Abbreviation Lane Recognized epitope(s)
Epitope(s)
Adducin a Adducin a 3 S726
Adducin g Adducin g 3 S693
B23 (nucleophosmin, numatrin, nucleolar protein NO38) B23 (NPM) 19 S4
Cyclin-dependent protein-serine kinase 1/2 CDK1/2 3 Y15
Double-stranded RNA-dependent protein-serine kinase PKR1 16 T451
Extracellular-regulated protein-serine kinase 2 ERK2 8 T185+Y187
Jun N-terminus protein-serine kinase JNK 6 T183+Y185
Stress-activated protein kinase (SAPK)
Jun proto-oncogene-encoded AP1 transcription factor Jun 11 S73
MAPK/ERK protein-serine kinase 1/2 MEK1/2 19 S218+S222
Mitogen-activated protein-serine kinase p38 alpha p38a MAPK 18 T180+Y182
N-methyl-D-aspartate (NMDA) glutamate receptor 1 NR1 2 S896
Protein-serine kinase B alpha (Akt1) PKBa (Akt1) 13 S473
Protein-serine kinase C epsilon PKCe 9 S729
Ribosomal S6 protein-serine kinase 1/3 RSK1/3 6 T359+S363/T356+S360
Signal transducer and activator of transcription 1 STAT1 12 Y701
Signal transducer and activator of transcription 5 STAT5 4 Y694
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Figure 4 |Western blot. Effects of 2-week infusion of the pressor
dose of angiotensin (Ang II) and concurrent losartan treatment on
cAMP-dependent phospho-CREB1 [S133] immunofluorescence
staining (a–c, not quantitative) or CREB1 [S133] phosphoproteins
(d, semi-quantitative) in proximal tubules of the rat kidneys.
Phospho-CREB1 [S133] is expressed as a fraction of non-
phosphorylated CREB1 proteins. In each lane of western blot gels,
100mg proteins were loaded. **Po0.01 versus control; wwPo0.01
versus Ang II-infused rats. G, glomerulus; PT, proximal tubule.
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Figure 5 |Western blot. Effects of 2-week infusion of the pressor
dose of angiotensin (Ang) II and concurrent losartan treatment on
phosphorylated protein-serine kinase C (PKC)a [S657]
immunofluorescence staining (a–c, not quantitative) or PKCa
[S657] phosphoproteins (d, semi-quantitative) in proximal tubules
of the rat kidneys. Phosphorylated or activated PKCa [S657] is
expressed as a fraction of non-phosphorylated PKCa proteins.
In each lane of western blot gels, 100 mg proteins were loaded.
#Po0.05 versus membrane fraction; **Po0.01 versus control;
wwPo0.01 versus Ang II-infused rats. G, glomerulus; PT, proximal
tubule.
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phosphorylation of NHE-3 proteins in wild-type mouse
proximal tubule cells. Ang II induced both dose- and time-
dependent increases in phospho-NHE-3 proteins with peak
responses at 1 to 10 nmol/l (Figure 12a), and at 5 to 10min
after Ang II stimulation (Figure 12b). The effect of Ang II
(1 nmol/l) on activation of NHE-3 proteins was inhibited by
knocking down the expression of PKCa signaling proteins
with a specific PKCa siRNA, but not with a scrambled siRNA
control (Figure 12c).
DISCUSSION
Although proteomic approaches are increasingly used to
identify novel proteins in target tissues, few studies have
used these techniques to profile pathway-specific signaling
responses to 2 weeks of Ang II infusion specifically in
proximal tubules of the kidney.18 Leong et al.19 used one-
dimensional SDS-PAGE and MALDI-MS analyses to study
the trafficking of renal cortical membrane transporter
proteins in response to acute angiotensin-converting enzyme
inhibition with captopril in rats. Using these techniques,
Leong et al.19 were able to characterize the patterns of
redistribution of NHE-3, NaPi2, and vacuolar Hþ -ATPases
in the rat renal cortex after acute angiotensin-converting
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enzyme inhibition. de Borst et al.20 used novel peptide array
chips to profile protein kinase substrates and/or protein
kinase activities in the renal cortex of homozygous Ren2 rats,
a model of Ang II-dependent hypertension. The notable
observations in the latter study are the activation of p38 MAP
kinase and the platelet-derived growth factor receptor-b,
which were increased in Ren2 and reversed by ramipril.20 The
present study differs from the abovementioned studies in
three unique ways. First, only freshly isolated proximal
tubules were used for analysis of signaling responses, which
exclude the contamination of signaling proteins from other
cellular structures. Second, we used the pathway-specific,
multi-immunoblotting approach for proteomic analysis of
signaling responses to 2 weeks of pressor or non-pressor dose
of Ang II infusion with or without hypertension. Finally,
we used antibodies that target specific phosphorylation sites
of the proteins of interest. This pathway-specific multi-
immunoblotting analysis revealed several key signaling
responses in proximal tubules of rats infused with the pressor
or the non-pressor dose of Ang II.
Inhibition of cAMP-dependent activation of CREB1 [S133]
signaling phosphoproteins by the pressor dose of Ang II
Ang II regulates proximal tubule sodium and bicarbonate
reabsorption in part by inhibiting adenylate cyclase and
cAMP.21,22 Although it remains controversial, there is
evidence that Ang II inhibits cAMP production in proximal
tubule cells.23–25 Conversely, increases in cAMP and activa-
tion of cAMP-dependent PKA inhibit Ang II-induced
acidification of proximal tubule fluid or apical Naþ /Hþ
exchange in isolated perfused proximal tubules.22,23 Phos-
pho-CREB1 [S133] is the major downstream signaling
protein in response to activation of cAMP-dependent PKA
and was measured as a function of cAMP activation in the
present study. We found a B60% decrease in phospho-
CREB1 [S133] proteins in proximal tubules of rats infused
with the pressor dose Ang II and the effect was blocked by
losartan treatment. These responses were confirmed in
phospho-CREB1-immunofluorescence staining in proximal
tubules of Ang II-infused rats treated with or without
losartan. However, we did not observe similar changes in
phospho-CREB1 [S133] proteins in proximal tubules of rats
infused with the non-pressor dose of Ang II. This raises the
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Figure 8 |Western blot. Effects of 2-week infusion of the pressor
dose of Ang II and concurrent losartan treatment on
phosphorylated or activated NHE-3 immunofluorescence staining
(a–c, not quantitative) or phospho-NHE-3 protein abundance in
membrane fractions of proximal tubules of the rat kidney (d, semi-
quantitative). In each lane of western blot gels, 100 mg proteins
were loaded. **Po0.01 versus control; wwPo0.01 versus
angiotensin (Ang) II-infused rats. G, glomerulus;
PT, proximal tubule.
Table 3 | Effects of the non-pressor dose of Ang II infusion
and concurrent losartan treatment for 2 weeks on body
and kidney weights, systolic blood pressure, 24 h urinary
excretion of water, and electrolytes in Ang II-infused rats
Response Control
Non-pressor
Ang II
Non-pressor
Ang II + Los
Body weight, g 314±11 328±9 298±7
Kidney weight, g 2.4±0.07 2.6±0.1 2.37±0.03
Kidney weight/ 0.77±0.02 0.78±0.02 0.79±0.01
body weight ratio, 100
SBP, mm Hg 115±4 116±3 105±6
Urine, ml/24 h 15.5±0.5 17.8±0.9 19.1±3.0
UNaV, mmol/24 h 2.35±0.2 1.93±0.2 1.98±0.25
UKV, mmol/24 h 3.2±0.6 4.8±0.22** 2.73±0.36
w
Urine osmolality, mOsm/kg H2O 1418±35 1084±56* 1028±151*
Abbreviations: Ang, angiotensin; SBP, systolic blood pressure; UKV, urinary
potassium excretion; UNaV, urinary sodium excretion. *Po0.05 or **Po0.01 versus
control. wPo0.05 versus the non-pressor Ang II-treated group.
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Figure 9 |Western blot. Effects of 2-week infusion of the non-
pressor dose of Ang II and concurrent losartan treatment on
phosphorylated or activated NHE-3 immunofluorescence staining
(a–c, not quantitative) or phospho-NHE-3 protein abundance in
membrane fractions of proximal tubules of the rat kidney (d, semi-
quantitative). In each lane of western blot gels, 100mg proteins
were loaded. **Po0.01 versus control; wwPo0.01 versus
angiotensin (Ang II)-infused rats. G, glomerulus;
PT, proximal tubule.
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possibility that the response of phospho-CREB1 [S133]
proteins to the pressor dose of Ang II in proximal tubules
may be pressure-dependent.
Activation of PKC signaling phosphoproteins
The phospholipase C-dependent PKC signaling pathway
represents a major cellular mechanism underlying Ang II-
induced transport responses in proximal tubules.5,26–28 In the
present study, we focused on four major phospho-PKC
isoenzymes, PKCa, PKCbII, PKCd, and PKCe, because these
PKC isoenzymes are expressed and respond to Ang II in the
rat and mouse kidneys29,30 or in rat proximal tubules.27,31
As both phospho-PKCa [S657] and phospho-PKCbII
were increased by Ang II and attenuated by losartan, an
AT1 receptor-mediated mechanism is clearly indicated. By
comparison, only phospho-PKCa [S657] and phospho-PKCd
[T507] proteins were increased in proximal tubules by the
non-pressor dose of Ang II. These results suggest that PKCa
and PKCd may be directly activated by Ang II, independent
of blood pressure, whereas the response of PKCbII may be
pressure-dependent. Previous studies showed that Ang II
had no effect on PKCd or increased PKCe27 or PKCg activity
in proximal tubules.31 By contrast, the present study showed
that PKCd [T507] phosphoproteins were decreased byB59%
without altering PKCe [S729] in proximal tubules of rats
infused with the pressor dose of Ang II. These differences
may be explained by our use of freshly isolated proximal
tubules and measurement of activated or phosphorylated
PKC isozymes, and treatment of rats with Ang II for 2 weeks.
A substantial increase in activated PKCd [T507] in proximal
tubules of rats infused with the non-pressor dose of Ang II
and with normal blood pressure is consistent with this
interpretation.
Activation of GSK3a and GSK3b signaling phosphoproteins
GSK3 is associated with glycogen metabolism, glucose
transport, insulin receptor signaling, and proliferative
cytokines.32–34 GSK3a and GSK3b are serine/threonine
protein kinases and their activation induces phosphorylation
of glycogen synthase leading to inactivation of this enzyme
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Figure 10 |The Kinetwork multi-immunoblot comparison analyses identified seven signaling phosphoproteins that were altered
in proximal tubules of the rat kidneys by 2-week infusion of the non-pressor dose of Ang II. (a) A multi-immunoblot from
pooled control proximal tubule samples. (b) A multi-immunoblot from pooled Ang II-infused proximal tubule samples. (c) The colored
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quantity of the band corrected to a scan time of 60 sec (see online Expanded Methods section). ND, not determined.
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and increase of glucose levels. Mariappan et al.32 showed that
GSK3b has a role in augmented protein synthesis by high
glucose and in insulin-stimulated hypertrophy of renal
proximal tubular cells of type 2 diabetes. In human tubular
epithelial cells, tumor necrosis factor-a-mediated proinflam-
matory responses were augmented by GSK3b overexpression
and conversely obliterated by GSK3b inhibitors.33 How
GSK3a and GSKb are activated by Ang II remains to be
further studied. The differences in phospho-GSK3 (aþ b)
responses to the pressor and non-pressor doses of Ang II
suggest that activation of PKC by Ang II and hypertension
may have an important role.34
MAP kinases ERK1/2 signaling phosphoproteins
Activation of the MAP kinases ERK1/2 signaling cascade is a
major downstream signaling mechanism for Ang II-induced
growth and transcriptional responses.35,36 However, phos-
pho-Raf1 [S259], MEK3/6 [S189þ S207], or ERK1/ERK2
[T202þY204] were either decreased or remained unaltered
in proximal tubules of rats infused with the pressor dose of
Ang II, while the non-pressor dose of Ang II had no effects.
These in vivo findings are different from the acute effects of
Ang II on ERK1/2 activation in vitro in mesangial and
proximal tubule cells.37–40 The explanation may be that
Ang II was infused in rats for 2 weeks rather than minutes,
and the responses of the ERK1/2 signaling cascade may have
returned to the control level in the present study. Indeed, Ang
II acutely increased ERK1/2 phosphoproteins in both dose-
and time-dependent manners, which were blocked by
losartan, in wild-type mouse proximal tubule cells and
AT1a-KO mouse proximal tubule cells with the knock-in of
the AT1a receptor. Alternatively, activation of GSKa and
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cells. In each lane of western blot gels 10mg proteins were loaded.
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GSKb signaling by Ang II may inhibit the ERK signaling
pathway, as reported in cardiac cells and renal proximal
tubular cells.32,41
Correlations between Ang II-induced signaling phospho-
protein responses and activation of NHE-3
In the present study, a pressure-induced natriuretic response
was observed in rats infused with the pressor dose of
Ang II and with hypertension, and conversely, a small but
insignificant anti-natriuretic response was seen in rats
receiving the non-pressor dose of Ang II infusion without
hypertension. These different responses are associated with
the downregulation of AT1 receptor and decreases in
phospho-NHE-3 proteins in membrane fractions of proximal
tubules with the pressor dose of Ang II infusion. Combined
with the decreases in phopho-NHE-3 immunofluorescence
staining in proximal tubules, our results are consistent with
the concept that activated NHE-3 proteins may be decreased
and retracted from brush border membranes of proximal
tubules during acute and chronic hypertension.42,43 This
interpretation is supported by the findings that phospho-
NHE-3 proteins were increased in membrane fractions of
proximal tubules of the rats infused with the non-pressor
dose of Ang II in vivo (Figure 9b) and in cultured mouse
proximal tubule cells in vitro (Figure 12). Finally, activation
of PKCa signaling proteins by the pressor and non-pressor
dose of Ang II may be responsible for activation of NHE-3 in
proximal tubules, proximal tubule sodium transport, and
urinary sodium responses in the present study.5,26,27,31,44
In summary, the present study used the novel pathway-
specific, multi-immunoblotting proteomic approach for the
first time to simultaneously profile the sustained responses of
38 signaling phosphoproteins to a pressor or a non-pressor
dose of Ang II in freshly isolated proximal tubules of the rat
Table 4 | KINETWORKS KPSS 1.3 multi-immunoblotting screen tracking 38 phosphorylation sites of signaling phosphoproteins
with antibodies that recognize specific phosphorylated epitopes
Ab. # Protein Description of target protein Recognized epitope(s)
1. Adducin-a Adducin alpha (ADD1) S726
2. Adducing Adducin gamma (ADD3) S693
3. B23 [NPM] B23 (nucleophosmin, numatrin, nucleolar protein NO38) S4
4. CDK1/2 Cyclin-dependent protein-serine kinase 1/2 Y15
5. CREB1 cAMP-response element binding protein 1 S133
6. Erk1 Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) T202+Y204
7. Erk2 Extracellular regulated protein-serine kinase 2 (p42 MAP kinase) T185+Y187
8. GSK3a Glycogen synthase-serine kinase 3 alpha S21
9. GSK3a Glycogen synthase-serine kinase 3 alpha Y279
10. GSK3b Glycogen synthase-serine kinase 3 beta S9
11. GSK3b Glycogen synthase-serine kinase 3 beta Y216
12. JNK Jun N-terminus protein-serine kinase (stress-activated protein kinase
(SAPK)) 1/2/3
T183+Y185
13. Jun Jun proto-oncogene-encoded AP1 transcription factor S73
14. MEK1/2 MAPK/ERK protein-serine kinase 1/2 (MKK1/2) S217+S221
15. MEK3/6 MAP kinase protein-serine kinase 3/6 (MKK3/6) S189/S207
16. MEK6 (MAP2K6) MAP kinase protein-serine kinase 6 (MKK6) S207
17. Msk1 Mitogen- and stress-activated protein-serine kinase 1 S376
18. NR1 N-methyl-D-aspartate (NMDA) glutamate receptor 1 subunit zeta S896
19. p38a MAPK Mitogen-activated protein-serine kinase p38 alpha T180+Y182
20. PKBa [Akt1] Protein-serine kinase B alpha (Akt1) T308
21. PKBa [Akt1] Protein-serine kinase B alpha (Akt1) S473
22. PKCa Protein-serine kinase C alpha S657
23. PKCab2 Protein-serine kinase C alpha/beta 2 T638/T641
24. PKCd Protein-serine kinase C delta T507
25. PKCe Protein-serine kinase C epsilon S729
26. PKR Double-stranded RNA-dependent protein-serine kinase T451
27. Raf1 Raf 1proto-oncogene-encoded protein-serine kinase S259
28. Rb Retinoblastoma-associated protein S780
29. Rb Retinoblastoma-associated protein S807+S811
30. RSK1/3 Ribosomal S6 protein-serine kinase 1/3 T359+S363/T356+S360
31. S6K2 p85 p85 ribosomal protein-serine S6 kinase 2 T412
32. S6Kap70 p70 ribosomal protein-serine S6 kinase alpha T389
33. Smad1/5/9 SMA- and mothers against decapentaplegic homologs
1/5/9
S463+S465/S463+S465/S465+S467
34. Src Src proto-oncogene-encoded protein-tyrosine kinase Y418
35. Src Src proto-oncogene-encoded protein-tyrosine kinase Y529
36. STAT1 Signal transducer and activator of transcription 1 Y701
37. STAT3 Signal transducer and activator of transcription 3 S727
38. STAT5 Signal transducer and activator of transcription 5 Y694
Abbreviations: Ab., antibody; S, serine; T, threonine; Y, tyrosine.
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kidney. The activated signaling phosphoproteins by Ang II
identified in the present study may have diverse physiological
and pathophysiological effects on sodium and fluid reabsorp-
tion (cAMP/PKA/CREB1, PKCa, PKCbII, and PKCd), and
glycogen metabolism and glucose transport (GSK3a and
GSK3b) in proximal tubules. These responses were likely
mediated by AT1 receptors, because losartan largely blocked
Ang II receptors in the kidney and the responses of signaling
proteins in Ang II-infused rats. However, it should be pointed
out that some of the losartan-mediated effects may be
independent of AT1 receptor blockade; for example, losartan
may directly or indirectly inhibit angiotensin-converting
enzyme and therefore decreases Ang II formation. Never-
theless, our results suggest that multi-immunoblot proteomic
analysis of pathway-specific signaling phosphoproteins may
provide a powerful tool to identify novel signaling mechan-
isms or therapeutic targets in Ang II-induced hypertension
and kidney diseases.
MATERIALS AND METHODS
See Online Expanded Methods for details.
Animals
A total of six groups of 54 adult male Sprague–Dawley rats were used
in this study. Groups 1 and 4 were used as control. Groups 2 and 5
were infused with the pressor (60 ng/min) or the non-pressor dose
(15 ng/min) of Val5-Ang II via an osmotic minipump for 2 weeks.
Groups 3 and 6 were infused with Ang II as in Groups 2 and 5 but
treated with the AT1 receptor antagonist, losartan, at 20mg/kg per
day, p.o. for 2 weeks. Systolic blood pressure and 24-h urine and
urinary sodium excretion were measured as described.12,45,46 This
study was approved by the Henry Ford Health System and
University of Mississippi Medical Center’s Institutional Animal
Care and Use Committees, respectively.
Isolation of fresh proximal tubules
Fresh and pure proximal tubules (B95%) were isolated from the
superficial cortex of the kidneys of control, Ang II-infused, and
losartan-treated Ang II-infused rats using a modified method of
Vinay et al.47 (Supplementary Figure S5 online).
Measurements of plasma, whole kidney, and proximal tubule
Ang II
Plasma, kidney, and proximal tubular Ang II concentrations were
measured using a sensitive Ang II ELISA kit after extraction and
purification.12,45,46
Measurement of urine and urinary electrolyte excretion
Twenty-four hour urine excretion rate was determined gravimet-
rically, whereas urinary sodium and potassium concentrations were
determined by Nova 13 Electrolyte Analyzer (Waltham, MA).12,45,48
Urine albumin and creatinine concentrations were measured to
determine the albumin-to-creatinine ratio as an index of renal injury.
Pathway-specific multi-immunoblotting proteomic analysis
of signaling phosphoproteins
Proteins were extracted from freshly isolated proximal tubules
according to the Services Provider’s protocol for multi-immuno-
blotting of signaling phosphoproteins (Kinexus Bioinformatics).
Overall, 38 signaling phosphoproteins were profiled using a
Kinetworks pathway-specific phosphoprotein multi-immuno-
blotting screen (KPSS 1.3).49,50 The antibodies targeting specific
phosphoproteins are listed in Table 4.
Immunofluorescence staining of signaling phosphoproteins
Phospho-CREB1 (S133), phospho-PKCa (S657), phospho-NHE-3,
phospho-cJun (S73) (Supplementary Figure S6 online), phospho-Rb
(S807þ S811) (Supplementary Figure S9 online), phospho-Src
(Y418) (Supplementary Figure S7 online), phospho-Src (Y529)
(Supplementary Figure S8 online), and phospho-STAT3 (S727)
(Supplementary Figure S10 online) immunofluorescence staining in
proximal tubules were performed in kidney sections using the
primary antibodies as for western blot analysis.
Western blot analysis
Western blot analysis was performed to further confirm the extent of
responses in some, but not all, selective phosphoproteins using
antibodies that recognize the phosphorylation epitope(s).49,50
Statistical analysis
All results are presented as means±s.e.m. The differences in the
same parameters between different groups of rats were first
analyzed using one-way analysis of variance followed by Dunnett’s
comparisons between group means. For multi-immunoblotting
analysis, the data were pooled from five rats for each group. For
standard western blot analysis, data were derived from six rats
for each group. The significance was set at Po0.05.
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Figure S1. Effects of the pressor dose of Ang II and concurrent
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losartan treatment on proximal tubular phospho-ERK1/2 signaling
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Figure S6. Effect of the pressor dose of Ang II on proximal tubular
phosphorylated c-Jun [S73] immunofluorescence staining.
Figure S7. Effect of the pressor dose of Ang II on proximal tubular
phosphorylated Src [Y418] immunofluorescences staining.
Figure S8. Effect of the pressor dose of Ang II on proximal tubular
phosphorylated c-Jun[Y529] immunofIuorescence staining.
Figure S9. Effect of the pressor dose of Ang II on proximal tubular
phosphorylated Rb [807+S811] immunofluorescence staining.
Figure S10. Effect of the pressor dose of Ang II on proximal tubular
phosphorylated STAT-3[S727] immunofluorescence staining.
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